Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Contract Manufacturer Starts Life As DPx

by Rick Mullin
March 17, 2014 | A version of this story appeared in Volume 92, Issue 11

The contract drug development and manufacturing firm conceived last year through the $2.65 billion merger of Patheon and DSM’s pharmaceutical services business was finalized and launched last week under the name DPx Holdings. The new firm is owned 49% by DSM and 51% by JLL Partners, a private equity firm that held a majority stake in Patheon. Based in Durham, N.C., DPx will have 24 locations across North America, Europe, Latin America, and Australia that provide contract manufacturing and formulation services. With the finalization of the deal, DSM has completed the disbanding of its pharmaceutical business.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.